Cardiff Oncology Inc reports results for the quarter ended March 31 - Earnings Summary

Cardiff Oncology

08/05/2025 22:02

Cardiff Oncology Inc CRDF.OQ reported a quarterly adjusted loss of 20 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -22 cents.  The mean expectation of seven analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -23 cents to -14 cents per share.

Revenue fell 46.8% to $109.00 thousand from a year ago; analysts expected $96.43 thousand.

Cardiff Oncology Inc's reported EPS for the quarter was a loss of 20 cents​.

The company reported a quarterly loss of $13.44 million.

Cardiff Oncology Inc shares had fallen by 20.7% this quarter and lost 42.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 17.3% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cardiff Oncology Inc is $14.00

This summary was machine generated from LSEG data May 8 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.19
-0.20
Missed
Dec. 31 2024
-0.24
-0.22
Beat
Sep. 30 2024
-0.27
-0.25
Beat
Jun. 30 2024
-0.25
-0.26
Missed